
One has to wonder whether it would be in the best interests of all involved parties to require redesign of these devices in order to lessen the risk of transmission of infection.
The U.S. Food and Drug Administration (FDA) has been working with the manufacturers of several devices, including duodenoscopes, to improve their cleaning procedures. However, the issue with duodenoscopes is that despite following strict manufacturer’s instructions, which several facilities have done, these devices are very difficult to clean due to their intricate design and that is a huge area of concern.
FDA is convening an advisory panel next week to discuss recent CRE outbreaks, and the hope is that they will be able to recommend further steps for all involved with ERCP to protect patients from undesirable consequences.
While infection prevention practices have made great progress in recent years, we still have a long way to go in the interest of patient safety. This is a multi-disciplinary need, and one that must involve regulatory agencies as well as manufacturers and healthcare personnel.